Discover and read the best of Twitter Threads about #ACCPAM19
Most recents (6)
@ErinMcCreary taking the stage on an ID Literature Update
Duration of therapy is 🔥 right now. #ACCPAM19 #ACCP @accpinfdprn
Duration of therapy is 🔥 right now. #ACCPAM19 #ACCP @accpinfdprn
Each additional day of ABX therapy ⤴️harm is both 👶 and 🧑 s!
🛑Each extra day of 💊 in Peds ➡️⤵️anaerobic microflora⤴️rates of C.diff and infectious complications
In surgical PTH➡️each➕ABX day had no proven mortality benefit but ⤴️AKI risk with a NNH of 4 😮 @ErinMcCreary
🛑Each extra day of 💊 in Peds ➡️⤵️anaerobic microflora⤴️rates of C.diff and infectious complications
In surgical PTH➡️each➕ABX day had no proven mortality benefit but ⤴️AKI risk with a NNH of 4 😮 @ErinMcCreary
@ErinMcCreary stresses an important point, TRANSITION OF CARE IS 🔑
More patients receive extended duration of ABX therapy when transitioned from IV to PO, inpatient to outpatient as the TOTAL duration of therapy we should be keeping an 👁 on!
More patients receive extended duration of ABX therapy when transitioned from IV to PO, inpatient to outpatient as the TOTAL duration of therapy we should be keeping an 👁 on!
Getting the LOW down on the LDL management! Credit to @DaveDixonPharmD to the great comparison slides on the updated cholesterol guidelines #ACCPAM19
First update ☝️
Lipid measurement can be fasting OR non-fasting! 👏🏻
However important to note 📝 LDL-C May UNDERestimate the true LDL-C if the LDL is <70 mg/dL. In this case use of non-HDL may be a more accurate marker.
Lipid measurement can be fasting OR non-fasting! 👏🏻
However important to note 📝 LDL-C May UNDERestimate the true LDL-C if the LDL is <70 mg/dL. In this case use of non-HDL may be a more accurate marker.
Primary prevention of ASCVD.. its complicated 🤯
✅ Important to 📝 patient specific factors&risk stratify to identify where your patient fits along the spectrum of ASCVD risk & @DaveDixonPharmD stresses the importance of the patient centered discussion on pharmacologic therapy
✅ Important to 📝 patient specific factors&risk stratify to identify where your patient fits along the spectrum of ASCVD risk & @DaveDixonPharmD stresses the importance of the patient centered discussion on pharmacologic therapy
OP-timizing anticoagulation in the Peri-OPerative period. 🏥💉 @accpcritprn @accpcardprn #ACCPAM19 #ACCP
Optimization through risk stratification. All about weighing the risk of thrombosis vs. the risk of bleeding. Audrey stressed the importance of individualizing the plan to restart AC based on patient specific factors!
But it’s clear to say, bridging anticoagulation should be put at bay! Literature suggests bridging only increases the risk of bleeding without any reduction in the risk of thrombosis! @AccpPeriopPRN
Putting a CAP on the recommendations for community acquired pneumonia, here’s the tweetorial promised below! 🔑 pearls on the 2019 updates! 📝 #ACCPAM19
Top of the iceberg was a discussion of DUAL vs. MONOtherapy: is BL therapy alone ✅ for CAP? 🤔
Not so fast! 🏃
BL monotherapy has yet to take prime time, up to 40% of patients received atypical coverage in the CAP-START study. So for now, ✌️ is > ☝️
Not so fast! 🏃
BL monotherapy has yet to take prime time, up to 40% of patients received atypical coverage in the CAP-START study. So for now, ✌️ is > ☝️
Next up, HCAP is 💀 #nuffsaid
starting #ACCPAM19 with the amazing @emilylheil presenting an update on the recently-published community-acquired pneumonia #CAP guidelines ncbi.nlm.nih.gov/pubmed/31573350
@emilylheil So what actually causes CAP? @emilylheil states "the pathogenesis and etiology of CAP has changed over time with increased rates of vaccination and better diagnostics." Jain et al 2015 unable to identify a pathogen in > 60% of patients, viruses most common
ncbi.nlm.nih.gov/pubmed/26172429
ncbi.nlm.nih.gov/pubmed/26172429
@emilylheil Since etiology a great unknown, do we need to cover atypicals? Garin et al found BL monotherapy NOT non-inferior to combo, but on flip CAP-START suggested atypical coverage perhaps unneeded...
ncbi.nlm.nih.gov/pubmed/25286173
ncbi.nlm.nih.gov/pubmed/25830421
ncbi.nlm.nih.gov/pubmed/25286173
ncbi.nlm.nih.gov/pubmed/25830421
